Sam Altman is backing Merge Labs, a new brain-computer interface venture exploring a gene therapy approach to connect human brains with AI. The company is considering genetically modifying brain cells to respond to ultrasound, enabling a less invasive implant system. Merge is currently raising $250 million at an $850 million valuation, with major backing expected from OpenAI’s venture arm. This move positions Altman in direct competition with Elon Musk’s Neuralink, which uses electrode-based implants. Merge’s approach combines sonogenetics and embedded ultrasound hardware, aiming for high-bandwidth communication between thought and AI systems. Altman is co-founding the project but won’t take a day-to-day role or personally invest.